Figure 2. Primary endpoints (A) The least-squares mean proportion of patients with resolution of MASH without worsening of fibrosis after 24 weeks of treatment; error bars represent SE; MASH resolution was defined as at least a 2-point reduction in NAS (scale of 0 to 8, with higher scores indicating more severe disease), no hepatocyte ballooning, and a score of 0 or 1 in the lobular inflammation component of the score, without worsening fibrosis. (B) The least-squares mean proportion of patients with liver fibrosis improvement without worsening of MASH after 24 weeks of treatment, defined as the proportion of patients achieving at least a one-stage improvement in liver fibrosis without worsening of NAS; error bars represent SE. A composite strategy was employed that considered patients with missing outcomes due either to missing biopsies or treatment discontinuations as non-responders. Data were analysed with the use of the chi-square test. MASH=metabolic dysfunction-associated steatohepatitis. NAS=non-alcoholic fatty liver disease activity score.
Another G-force molecule
GLP + glucagon agonist #pemvidutide in MASH
Resolution of MASH, fibrosis impact not seen at this time
www.thelancet.com/journals/lan... in @thelancet.com
How long till someone (?Pfizer) gobbles up Altimmune? @rnflex.bsky.social
